Next Article in Journal / Special Issue
Vaccination against δ-Retroviruses: The Bovine Leukemia Virus Paradigm
Previous Article in Journal
Engineered RNase P Ribozymes Effectively Inhibit Human Cytomegalovirus Gene Expression and Replication
Previous Article in Special Issue
Infection with Non-Lethal West Nile Virus Eg101 Strain Induces Immunity that Protects Mice against the Lethal West Nile Virus NY99 Strain
Article Menu

Export Article

Open AccessReview
Viruses 2014, 6(6), 2392-2415; doi:10.3390/v6062392

Alphavirus-Based Vaccines

PanTherapeutics, Rue des Remparts 4, CH1095 Lutry, Switzerland
Received: 2 April 2014 / Revised: 3 June 2014 / Accepted: 4 June 2014 / Published: 16 June 2014
(This article belongs to the Special Issue Virus-based Vaccines)
View Full-Text   |   Download PDF [742 KB, uploaded 12 May 2015]   |  


Alphavirus vectors have demonstrated high levels of transient heterologous gene expression both in vitro and in vivo and, therefore, possess attractive features for vaccine development. The most commonly used delivery vectors are based on three single-stranded encapsulated alphaviruses, namely Semliki Forest virus, Sindbis virus and Venezuelan equine encephalitis virus. Alphavirus vectors have been applied as replication-deficient recombinant viral particles and, more recently, as replication-proficient particles. Moreover, in vitro transcribed RNA, as well as layered DNA vectors have been applied for immunization. A large number of highly immunogenic viral structural proteins expressed from alphavirus vectors have elicited strong neutralizing antibody responses in multispecies animal models. Furthermore, immunization studies have demonstrated robust protection against challenges with lethal doses of virus in rodents and primates. Similarly, vaccination with alphavirus vectors expressing tumor antigens resulted in prophylactic protection against challenges with tumor-inducing cancerous cells. As certain alphaviruses, such as Chikungunya virus, have been associated with epidemics in animals and humans, attention has also been paid to the development of vaccines against alphaviruses themselves. Recent progress in alphavirus vector development and vaccine technology has allowed conducting clinical trials in humans.
Keywords: alphaviruses; vaccines; naked RNA; DNA vaccines; recombinant particles; protection against lethal virus challenges; tumor protection; clinical trials alphaviruses; vaccines; naked RNA; DNA vaccines; recombinant particles; protection against lethal virus challenges; tumor protection; clinical trials
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lundstrom, K. Alphavirus-Based Vaccines. Viruses 2014, 6, 2392-2415.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top